Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CMPINASDAQ:ERYPNASDAQ:INMBNASDAQ:LOGCNASDAQ:PDLI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPICheckmate Pharmaceuticals$10.50$10.46$2.00▼$10.50$231.40M-4.81142,261 shsN/AERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AINMBINmune Bio$10.10-0.4%$11.53$6.50▼$14.74$183.82M1.9995,375 shs10,728 shsLOGCLogicBio Therapeutics$2.07$2.06$0.26▼$3.77$68.23M4.61652,526 shsN/APDLIPDL BioPharma$2.47$2.47$2.09▼$3.86N/AN/AN/AN/A7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPICheckmate Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ERYPERYTECH Pharma0.00%0.00%0.00%-34.74%+241.71%INMBINmune Bio-4.56%+10.82%-16.89%-13.18%+33.60%LOGCLogicBio Therapeutics0.00%0.00%0.00%0.00%0.00%PDLIPDL BioPharma0.00%0.00%0.00%0.00%0.00%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AINMBINmune Bio0.7938 of 5 stars3.50.00.00.01.71.70.0LOGCLogicBio TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APDLIPDL BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPICheckmate PharmaceuticalsN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AINMBINmune Bio3.00Buy$16.0058.42% UpsideLOGCLogicBio TherapeuticsN/AN/AN/AN/APDLIPDL BioPharmaN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPICheckmate PharmaceuticalsN/AN/AN/AN/A$2.50 per shareN/AERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88INMBINmune Bio$160K1,148.88N/AN/A$2.07 per share4.88LOGCLogicBio Therapeutics$5.41M12.61N/AN/A$0.48 per share4.31PDLIPDL BioPharmaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPICheckmate Pharmaceuticals-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/AERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AINMBINmune Bio-$30.01M-$1.67N/A∞N/A-19,360.00%-64.11%-45.57%5/1/2024 (Estimated)LOGCLogicBio Therapeutics-$40.03M-$0.81N/AN/AN/A-246.71%-115.29%-53.01%N/APDLIPDL BioPharmaN/AN/A0.00∞N/AN/AN/AN/AN/ALatest LOGC, INMB, PDLI, CMPI, and ERYP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023INMBINmune BioN/A-$0.47-$0.47-$0.47N/A$0.03 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/APDLIPDL BioPharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPICheckmate PharmaceuticalsN/A5.205.20ERYPERYTECH Pharma0.323.653.65INMBINmune BioN/A2.162.16LOGCLogicBio Therapeutics0.171.992.26PDLIPDL BioPharmaN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPICheckmate Pharmaceuticals74.56%ERYPERYTECH Pharma1.09%INMBINmune Bio12.72%LOGCLogicBio Therapeutics39.11%PDLIPDL BioPharmaN/AInsider OwnershipCompanyInsider OwnershipCMPICheckmate Pharmaceuticals62.60%ERYPERYTECH Pharma1.94%INMBINmune Bio36.10%LOGCLogicBio Therapeutics8.10%PDLIPDL BioPharma11.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCMPICheckmate Pharmaceuticals2822.04 million8.24 millionNot OptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableINMBINmune Bio1118.20 million11.63 millionOptionableLOGCLogicBio Therapeutics6232.96 million30.29 millionNot OptionablePDLIPDL BioPharma109N/AN/AOptionableLOGC, INMB, PDLI, CMPI, and ERYP HeadlinesSourceHeadlineGT Biopharma Inc GTBPmorningstar.com - February 23 at 6:12 PMHealth Winners & Losers: Maxygenthestreet.com - October 24 at 10:27 AMPDLI Historical Datainvesting.com - October 18 at 4:54 PMPDL stabbed by fellow inmatephilstar.com - September 23 at 11:42 PMABVC - ABVC BioPharma, Inc.finance.yahoo.com - June 28 at 6:50 PMRDHL - RedHill Biopharma Ltd.finance.yahoo.com - June 23 at 2:16 PMIntravenous Therapy for Hypertensive Emergencies, Part 2medscape.com - May 9 at 1:40 PMCheap Flights from Nuremberg to Ponta Delgadaskyscanner.net - April 21 at 4:32 PMCheap Flights from London to Ponta Delgadaskyscanner.net - April 16 at 7:28 PMIntravenous Therapy for Hypertensive Emergencies, Part 1medscape.com - April 12 at 5:47 PMLABPseekingalpha.com - March 12 at 9:26 PMPolaris Digitech Partners Google to Enhance Businesses Location Visibilitythisdaylive.com - March 11 at 9:19 AMCasdin Leads a Biopharma Surgeinstitutionalinvestor.com - February 23 at 8:29 PMA Persons Deprived of Liberty (PDL) interacts with his pet mouse inside the jailmsn.com - January 15 at 6:52 PMPDL BioPharma Stock To Go Ex-dividend Monday (PDLI)thestreet.com - January 4 at 11:32 PMPDL BioPharma Stock To Go Ex-dividend Tomorrow (PDLI)thestreet.com - December 14 at 3:41 PMKeeping Biogen Idec Innovative: Jim Mullen Interview (Part 2)xconomy.com - August 18 at 10:43 PMCramer's 'Mad Money' Recap: Politics Is Overratedthestreet.com - August 6 at 9:40 PMSteris (STE)forbes.com - May 21 at 11:08 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCheckmate PharmaceuticalsNASDAQ:CMPICheckmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.ERYTECH PharmaNASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.LogicBio TherapeuticsNASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.PDL BioPharmaNASDAQ:PDLIPDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.